Literature DB >> 9671408

PTEN/MMAC1/TEP1 involvement in primary prostate cancers.

S Pesche1, A Latil, F Muzeau, O Cussenot, G Fournier, M Longy, C Eng, R Lidereau.   

Abstract

The PTEN/MMAC1/TEP1 gene, located at 10q23.3, is a tumor suppressor gene responsible for the familial cancer syndromes Cowden disease and Bannayan-Zonana syndrome, and is commonly somatically mutated in several types of cancers. Mutations of the PTEN gene have been found in prostate cancer cell lines and LOH at 10q22-24 in prostate tumors have also been described with a high frequency. To determine the role of this gene in prostate tumorigenesis, we therefore analysed 22 primary tumors for loss of heterozygosity (LOH) within the 10q22-23 region such that tumors hemizygous at those loci may be examined for somatic PTEN mutations. Losses of heterozygosity of at least one locus was found in 12 (55%) of the 22 tumors DNAs. Among these, six tumors exhibited allele loss in the interval between D10S1765 and D10S541 wherein lies the PTEN gene. We searched the entire coding region of PTEN for somatic mutations in these six tumors. One somatic mutation (17%), a 1 bp deletion, was detected in exon 7 of the gene, in one tumor, indicating that somatic mutations of the PTEN gene may occur in primary prostate tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9671408     DOI: 10.1038/sj.onc.1202081

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

Review 1.  Krüppel cripples prostate cancer: KLF6 progress and prospects.

Authors:  Goutham Narla; Scott L Friedman; John A Martignetti
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

2.  Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.

Authors:  Martina Rudelius; Stefania Pittaluga; Satoshi Nishizuka; Trinh H-T Pham; Falko Fend; Elaine S Jaffe; Leticia Quintanilla-Martinez; Mark Raffeld
Journal:  Blood       Date:  2006-04-27       Impact factor: 22.113

Review 3.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

Review 4.  Interdiction of sphingolipid metabolism to improve standard cancer therapies.

Authors:  Thomas H Beckham; Joseph C Cheng; S Tucker Marrison; James S Norris; Xiang Liu
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

5.  Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.

Authors:  B Kwabi-Addo; D Giri; K Schmidt; K Podsypanina; R Parsons; N Greenberg; M Ittmann
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

Review 6.  Clinical implications of PTEN loss in prostate cancer.

Authors:  Tamara Jamaspishvili; David M Berman; Ashley E Ross; Howard I Scher; Angelo M De Marzo; Jeremy A Squire; Tamara L Lotan
Journal:  Nat Rev Urol       Date:  2018-02-20       Impact factor: 14.432

7.  PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients.

Authors:  Tamara L Lotan; Bora Gurel; Siobhan Sutcliffe; David Esopi; Wennuan Liu; Jianfeng Xu; Jessica L Hicks; Ben H Park; Elizabeth Humphreys; Alan W Partin; Misop Han; George J Netto; William B Isaacs; Angelo M De Marzo
Journal:  Clin Cancer Res       Date:  2011-08-30       Impact factor: 12.531

8.  Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.

Authors:  Stephen J Murphy; Robert J Karnes; Farhad Kosari; B Edgardo R Parilla Castellar; Benjamin R Kipp; Sarah H Johnson; Simone Terra; Faye R Harris; Geoffrey C Halling; Janet L Schaefer Klein; Aqsa Nasir; Eric Bergstrahl; Laureano J Rangel; William R Sukov; George Vasmatzis; John C Cheville
Journal:  Mod Pathol       Date:  2015-11-27       Impact factor: 7.842

9.  Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif.

Authors:  Nick M Makridakis; Lúcio Fábio Caldas Ferraz; Juergen K V Reichardt
Journal:  Hum Mutat       Date:  2009-01       Impact factor: 4.878

Review 10.  Targeting prostate cancer based on signal transduction and cell cycle pathways.

Authors:  John T Lee; Brian D Lehmann; David M Terrian; William H Chappell; Franca Stivala; Massimo Libra; Alberto M Martelli; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2008-06-16       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.